OrbusNeich Medical Group Holdings Limited

HKSE 6929.HK

OrbusNeich Medical Group Holdings Limited EBITDA Margin for the year ending December 31, 2023: 35.07%

OrbusNeich Medical Group Holdings Limited EBITDA Margin is 35.07% for the year ending December 31, 2023, a 76.85% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • OrbusNeich Medical Group Holdings Limited EBITDA Margin for the year ending December 31, 2022 was 19.83%, a 178.08% change year over year.
  • OrbusNeich Medical Group Holdings Limited EBITDA Margin for the year ending December 31, 2021 was 7.13%, a -50.50% change year over year.
  • OrbusNeich Medical Group Holdings Limited EBITDA Margin for the year ending December 31, 2020 was 14.41%, a 38.28% change year over year.
  • OrbusNeich Medical Group Holdings Limited EBITDA Margin for the year ending December 31, 2019 was 10.42%.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
HKSE: 6929.HK

OrbusNeich Medical Group Holdings Limited

CEO Mr. David Chien
IPO Date Dec. 23, 2022
Location Hong Kong
Headquarters Building 20E
Employees 1,278
Sector Healthcare
Industries
Medical Instruments 3D Printing Biotechnology Dental Care Insurance Investment Banking & Asset Management Stock Exchanges & Brokers Tobacco
Description

OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company was founded in 2001 and is headquartered in Shatin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.

StockViz Staff

February 4, 2025

Any question? Send us an email